Temozolomide: Small-Molecule Alkylating Agent for Glioma Res
2026-07-03
Temozolomide, a benchmark small-molecule alkylating agent, empowers researchers to dissect DNA repair and chemotherapy resistance in glioma and other cancer models with precision. Recent studies highlight its unique toxicity profile in ATRX-deficient cells and its versatility in combinatorial workflows, making it a cornerstone for advanced translational oncology research.
iRhom2 Regulates Olfactory Receptor Adaptation in Mice
2026-07-03
This study uncovers a novel function for iRhom2 in olfactory sensory neurons, linking its activity to odorant receptor regulation and feedback adaptation. The findings highlight iRhom2/ADAM17 signaling as a mechanism enabling olfactory neurons to adjust receptor expression in response to environmental stimuli, with implications for sensory biology and GPCR signaling research.
ABT-199 (Venetoclax): Precision Tools for Apoptosis Assays
2026-07-02
ABT-199 (Venetoclax) delivers unmatched selectivity for Bcl-2, enabling precise dissection of mitochondrial apoptosis in hematologic malignancy and fibrosis research. This guide translates recent breakthroughs into practical workflows, troubleshooting strategies, and advanced applications for researchers seeking reproducible, high-impact results.
PYR-41 and Ubiquitin-Activating Enzyme E1: Immune Modulation
2026-07-02
Explore the mechanistic depth and unique immunological applications of PYR-41, an inhibitor of Ubiquitin-Activating Enzyme E1. Discover how its intersection with NF-κB signaling and B cell activation informs advanced research strategies in cancer and inflammation.
Applied Cancer Research with MLN8237 (Alisertib): Protocols
2026-07-01
MLN8237 (Alisertib) stands out as a selective Aurora A kinase inhibitor, enabling precise dissection of oncogenic signaling and apoptosis induction in cancer models. This guide translates recent retinoblastoma research and hands-on workflow enhancements into actionable protocols and troubleshooting strategies for cancer biology labs.
FPR2/ALX Activation Restricts Autoimmune Astrocytopathy via
2026-07-01
This study reveals that stimulating the FPR2/ALX receptor with Quin-C1 suppresses neuroinflammation in a mouse model of autoimmune astrocytopathy by modulating microglia and natural killer cell activity. The findings clarify the SYK-AKT signaling mechanism and highlight new immunomodulatory strategies for neuroinflammatory diseases such as NMOSD.
A Multimodal iPSC Platform for Cystic Fibrosis Drug Testing
2026-06-30
This article explores the development of a patient-specific iPSC-derived airway epithelial cell platform for cystic fibrosis drug testing. The reference study demonstrates genotype-specific assessment of CFTR function and modulator response, providing a foundation for advancing therapeutics, especially for rare CFTR variants.
LGK-974: Redefining Wnt Pathway Inhibition for Translational
2026-06-30
This thought-leadership article explores how LGK-974, a potent PORCN inhibitor, is transforming the landscape of Wnt pathway research and translational oncology. We synthesize foundational developmental biology, state-of-the-art preclinical evidence, and strategic protocol guidance, emphasizing how this tool enables researchers to navigate the complexities of Wnt-driven cancers—especially those with RNF43 mutations. By connecting mechanistic insights to emerging translational strategies, we provide a forward-looking perspective for scientists aiming to bridge the gap between fundamental discovery and therapeutic innovation.
Adefovir-Induced Hypophosphatemic Osteochondrosis Mimics AS
2026-06-29
This reference study presents a clinical case in which chronic adefovir therapy for hepatitis B virus resulted in hypophosphatemic osteochondrosis, closely imitating the clinical and imaging features of ankylosing spondylitis (AS). The findings emphasize the need for careful differential diagnosis in HBV patients presenting with musculoskeletal symptoms, as drug-induced metabolic bone disease can be misinterpreted as inflammatory spondyloarthropathy.
SGI-1027: DNA Methyltransferase Inhibitor for Cancer Epigene
2026-06-29
SGI-1027 enables robust DNA methylation inhibition and selective DNMT1 degradation, unlocking advanced gene reactivation and tumor suppression workflows. Its unique dual mechanism facilitates precise modeling of cancer epigenetic therapies, with recent research highlighting optimal use strategies for maximal impact.
Poly (I:C): Protocols and Innovations in Immune Activation
2026-06-28
Poly (I:C), a synthetic double-stranded RNA analog, is revolutionizing immunology workflows by reliably inducing interferon and dendritic cell maturation. This article delivers fresh protocol strategies, troubleshooting insights, and practical advice grounded in recent breakthroughs for researchers aiming to model innate immune responses with precision.
Rotavirus NSP4 Drives Necroptosis via RIPK1-RIPK3-MLKL Axis
2026-06-27
This study reveals that rotavirus non-structural protein 4 (NSP4) orchestrates necroptotic cell death by engaging the host RIPK1-RIPK3 complex and inducing cytosolic calcium efflux, culminating in MLKL-dependent necroptosis. These findings clarify upstream signaling mechanisms and position calcium disruption as a pivotal step in rotavirus-induced cell death.
QSHXO Relieves MASLD via Autophagy Activation and Ferroptosi
2026-06-26
Liu et al. demonstrate that Qushi Huoxue ointment (QSHXO) alleviates metabolic associated steatotic liver disease (MASLD) in mice by promoting autophagy and inhibiting ferroptosis. Their findings clarify how coordinated modulation of these pathways can reduce hepatic lipid accumulation and inflammation, offering mechanistic guidance for targeted MASLD interventions.
CDK9 Inhibitor (A3294): Technical Workflow and Protocol Guid
2026-06-26
The CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor designed for precise modulation of cyclin dependent kinase 9 activity. It is well-suited for investigating transcription elongation inhibition and HIV-1 propagation inhibition in cell-based assays, but is not appropriate for experiments requiring broad-spectrum CDK inhibition or long-term working solution storage.
Optimizing Assays with NADH (Reduced-form Nicotinamide Adeni
2026-06-25
This comprehensive guide addresses persistent challenges in cell viability, proliferation, and mitochondrial function assays, focusing on the reproducible use of NADH (Reduced-form Nicotinamide Adenine Dinucleotide) CAS No. 58-68-4 (SKU C8749). By analyzing real-world laboratory scenarios, we illustrate how this rigorously characterized reagent from APExBIO supports reliable data generation and highlights best practices for mitochondrial electron transport chain research and disease modeling.
459 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page